Marc Diederich, Director of the LBMCC and principal investigator conducting independent research, leading and training a 25-person group including PhD and MSc students, runs us through the raison d’être of the Laboratory, how it is dedicated to the study of the cell and molecular biology of cancer and is focused on basic and applied research linking inflammation, cancer and leukemia.
The Laboratoire de Biologie Moléculaire et Cellulaire du Cancer (LBMCC) is a non-profit research laboratory dedicated to applied research linking inflammation, cancer and leukemia; differentiation therapy and novel therapeutic approaches for cancer based on compounds of natural origin. What made you originally decide to set up the laboratory back in 2002, and how would you say its scale and offering have evolved over the past 14 years?
Research in Luxembourg is generally very well appreciated by the public who can be very impatient at the apparent slow pace of investment from the public side.
